Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sales & Earnings

Set Alert for Sales & Earnings

J&J Lays Out ‘Responsibly Cautious’ Growth Outlook

The company's 2023 revenue guidance calls for 4.5%-5.5% growth, taking into account ongoing macroeconomic uncertainty and inflationary pressures.

Growth Sales & Earnings

Stock Watch: Spanners In The Works For Q4 Results

While the implications of the US Inflation Reduction Act are the focus of the sector’s concern this year, another regulatory development will impact earnings sooner.

Stock Watch Sales & Earnings

Biopharma Funding Contracted Last Year – And 2023 Will See The Squeeze Continue

Now the pandemic-era biotech boom is over, biopharma companies and investors are both adjusting their financing strategies to survive and even thrive in the new environment.

Commercial Companies

Scrip Asks…What Does 2023 Hold For Biopharma? Part 3: Global Headwinds

Headwinds of political instability, violent conflict, inflation and recession accompany us into 2023. Scrip surveyed industry leaders on the impacts for biopharma.

Scrip Asks Business Strategies

Cimzia Keeps Raking In The Cash As UCB Waits For New Products Impact

The Belgian group’s older products helped push 2022 revenues to the top of their guidance range as the peak sales forecast for the new epilepsy drug Fintepla is set at €800m.

Sales & Earnings Business Strategies

COVID-19 Windfalls Carry Pharma Into Stormy Times: Key Takeaways From Scrip 100 And Outlook 2023

The past couple of years have generated important growth for the pharma industry thanks to its drugs and vaccines for COVID-19. But with the IRA, high inflation, rising interest rates and chilly public markets, biopharma faces challenges this year. Here, we summarize key messages from In Vivo’s Outlook 2023.

Outlook 2023 Scrip 100

GloriaBio's Zimberelimab Experience Indicative Of China Commercial IO Challenges

As of October 2022, China's GloriaBio had reached less than 25% of the annual sales volume expected for its anti-PD-1 antibody zimberelimab and was set to miss its full-year target, forcing a CNY423m ($62m) impairment provision and illustrating how immuno-oncology fortunes can fluctuate in the country.

China Sales & Earnings

Stock Watch: Post-Pandemic Drug Commercialization Shifts

Emerging from the pandemic after nearly three years, therapy areas and drug classes are traveling at different speeds.

Stock Watch Advertising, Marketing & Sales

Stock Watch: Swelling Obesity Sales Boost Post-Pandemic Diabetes Drug Growth

The evolution of new drugs to treat diabetes has enabled some diabetes franchises to shrug off biosimilar competition to insulins. But is some of the growth of therapies for diabetes and obesity a result of the pandemic?

Stock Watch Sales & Earnings

Two Of Aurobindo’s Europe Biosimilar Filings Stuck, Licenses Ryzneuta From Yifan Pharma

Even as two biosimilar filings in Europe are stuck due to a lack of inspection staff and a biosimilar could be approved in the UK without a Phase III trial, Aurobindo has licensed novel drug Ryzneuta from Yifan Pharma. Meanwhile, a $650-700m revenue forecast for the specialty business has been pushed back as both overall revenues and profits declined during Q2.

Research & Development Commercial

Stock Watch: AstraZeneca’s Third-Quarter Crescendo

In a third-quarter earnings report that was difficult to fault AstraZeneca left big pharma earnings season on a high note. But raised full-year guidance depends on Evusheld sales and maybe China.

Stock Watch Sales & Earnings

Teva's New CEO Francis Takes Over A Steadier – Though Still Rocky – Organization

Teva announced the appointment of former Sandoz CEO Richard Francis as its next leader as Kare Schultz steps down.

Leadership Business Strategies
UsernamePublicRestriction

Register